Literature DB >> 1792008

Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour?

J Harro1, E Vasar.   

Abstract

Central cholecystokinin (CCK)-ergic neurotransmission has been implicated in the genesis of negative emotions. Most animal studies on the neurochemical background of CCK-induced anxiety have, up to date, exploited exploratory activity paradigms. The interaction of CCK with GABAergic inhibitory neurotransmission, mediated probably through CCK-B receptors, could be the neurochemical substrate for anxious type of exploratory behaviour. However, the CCK-A and CCK-B receptor-mediated interactions of this neuropeptide with mesencephalic dopaminergic regulation of motivation for locomotor activity have the potential to interfere with the behavioural outcome from routine exploratory activity tests. Systemic treatment with CCK receptor antagonists is likely to influence both GABA- and dopamine-linked CCK-ergic neurotransmission, and therefore their effects in exploratory activity tests should be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1792008     DOI: 10.1016/s0149-7634(05)80134-4

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  13 in total

1.  Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat.

Authors:  P W Frankland; S A Josselyn; J Bradwejn; F J Vaccarino; J S Yeomans
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

2.  Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice.

Authors:  Sirli Raud; Kertu Rünkorg; Alar Veraksits; Ain Reimets; Aleksei Nelovkov; Urho Abramov; Toshimitsu Matsui; Michel Bourin; Vallo Volke; Sulev Kõks; Eero Vasar
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

3.  The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.

Authors:  H J van Megen; H G Westenberg; J A den Boer; B Slaap; F van Es-Radhakishun; A C Pande
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

4.  Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze.

Authors:  E Vasar; E Peuranen; T Oöpik; J Harro; P T Männistö
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein.

Authors:  E Vasar; E Peuranen; J Harro; A Lang; L Oreland; P T Männistö
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

6.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

7.  Changes in cholecystokinin receptor binding in rat brain after selective damage of locus coeruleus projections by DSP-4 treatment.

Authors:  J Harro; S S Jossan; L Oreland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-10       Impact factor: 3.000

8.  Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.

Authors:  D Charrier; L Dangoumau; A J Puech; M Hamon; M H Thiébot
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

9.  Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.

Authors:  G R Dawson; N M Rupniak; S D Iversen; R Curnow; S Tye; K J Stanhope; M D Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

Review 10.  Understanding Emotions: Origins and Roles of the Amygdala.

Authors:  Goran Šimić; Mladenka Tkalčić; Vana Vukić; Damir Mulc; Ena Španić; Marina Šagud; Francisco E Olucha-Bordonau; Mario Vukšić; Patrick R Hof
Journal:  Biomolecules       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.